Project

Back to overview

Swiss HIV Cohort Study (SHCS)

English title Swiss HIV Cohort Study (SHCS)
Applicant Günthard Huldrych Fritz
Number 177499
Funding scheme Cohort Studies Large
Research institution Klinik für Infektionskrankheiten und Spitalhygiene Universitätsspital Zürich
Institution of higher education University of Zurich - ZH
Main discipline Internal Medicine
Start/End 01.01.2018 - 30.06.2021
Approved amount 8'167'252.00
Show all

All Disciplines (30)

Discipline
Internal Medicine
Clinical Nutritional Research
Clinical Pharmacology
Infectious Diseases
Nutritional Research, Vitaminology
Methods of Epidemiology and Preventive Medicine
Clinical Pathophysiology
Medical Microbiology
Paediatrics
Metabolic Disorders
Medical Statistics
Genetics
Cancer
Gynaecology
Addictive Diseases
Cardiovascular Diseases
Clinical Endocrinology
Experimental Microbiology
Mental Disorders, Psychosomatic Diseases
Medico-Social Problems of Youth
Ethology
Clinical Cardiovascular Research
Diseases of Bones and Joints
Immunology, Immunopathology
Pharmacology, Pharmacy
Clinical Cancer Research
Molecular Biology
Neurology, Psychiatry
Cellular Biology, Cytology
Clinical Immunology and Immunopathology

Keywords (25)

Immune deficiency; Antiretroviral therapy; HIV; Drug resistance; Transmission; Phylogenetics; Hepatitis C; Co-Infection; Sexually transmitted disease; Neutralizing antibodies; Latency; Morality; Co-morbidity; drug-drug interactions; Hepatitis B; Hepatitis Delta; Aging; host genetics; neurocognitive disorder; Migration; gender; HIV infected mothers; HIV infected children; side effects; pharmacodynamics

Lay Summary (German)

Lead
Die Schweizerische HIV Kohortenstudie (www.shcs.ch) ist eine klinische, multizentrische Langzeit-Studie, die HIV infizierte Menschen einschliesst. Sie forscht im Bereich der HIV-Medizin, der Grundlagen- und der Sozialen und Präventiven Wissenschaften. Sie wurde 1988 begonnen und schliesst bisher > 20'000 PatientInnen ein. Sie ist entscheidend für die hohe Qualität der HIV-Medizin in der Schweiz und für das bessere Verständnis der Wechselwirkung zwischen dem HI-Virus und dem menschlichen Organismus, kürzlich insbesondere auch zum besseren Verständnis des Entstehens von breit neutralisierenden Antikörpern in HIV-infizierten Individuen.
Lay summary
Die Schweizerische HIV Kohortenstudie (SHCS) wurde 1988 gestartet. Seither wurden > 20'000 PatientInnen eingeschlossen und 2017 wurden beinahe 10'000 aktiv betreut. 2003 wurde die Swiss Mother and Child HIV Cohort Study (MoCHIV) in die SHCS integriert. Schon früh vereinte die SHCS klinisch, translational, grundlagen- und sozial wissenschaftlich ausgerichtete Forschende. Bisher sind mehr als 1'000 in Fachzeitschriften erschienene wissenschaftliche Artikel aus der SHCS hervorgegangen, was deren Bedeutung unterstreicht. Eine ihrer Besonderheiten ist, dass sie jeweils rasch auf neue wissenschaftliche Erkenntnisse und Herausforderungen im Bereich der HIV-Forschung reagierte. Die SHCS ist repräsentativ für die Schweiz: mindestens 50% aller HIV-Infizierten, 75% aller PatientInnen mit AIDS und 75% aller Individuen in der Schweiz die antiretroviral behandelt werden nehmen an der Studie teil. Sie ist entscheidend für die hohe HIV-Behandlungsqualität in der Schweiz und leistet einen entscheidenden Beitrag zur Verhinderung von Neuinfektionen. Sie studiert medikamentöse Langzeitnebenwirkungen, Uebertragung von HIV, Koinfektionen und Resistenz, optimiert die antiretrovirale Therapie, bekämpft die Uebertragung von HIV von der Mutter auf das Kind und erforscht die Wechselwirkung zwischen dem HI Virus und dem menschlichen Organismus intensiv. Insbesondere laufen Studien, die letztlich auf die Entwicklung von Impfungen hinauslaufen und die verstehen helfen, warum es bisher nicht gelingt HIV zu heilen. Sozialwissenschaftliche Projekte laufen, um die Auswirkungen der HIV Infektion auf die Psyche und die Beschäftigungssituation zu verstehen. Zusammenfassend stellt die SHCS ein modernes Forschungsinstrument dar, das direkt den PatientInnen zu Gute kommt, einen grossen Beitrag zur Eindämmung der HIV-Epidemie in der Schweiz leistet und hilft, die Biologie der HIV Infektion im Menschen besser zu verstehen, was die Voraussetzung ist für eine wirksame Impfung oder eine Heilung.  
Direct link to Lay Summary Last update: 13.11.2017

Lay Summary (English)

Lead
The Swiss HIV Cohort Study (www.shcs.ch) is a multicenter, clinic based longitudinal study enrolling HIV infected individuals in Switzerland. It aims at performing research in the field of HIV medicine, basic and social sciences and public health. It started 1988, includes ~20'000 patients, is instrumental for the high quality of HIV-care in Switzerland, for monitoring the HIV epidemic and co-infections, and has contributed to better understanding interactions between HIV and the human host, in particular recently also elicitation of broadly neutralizing antibodies.
Lay summary
The SHCS is a fully established cohort that was started in 1988. Since then, > 20'000  patients were enrolled and in 2017, almost 10'000 were followed actively. From the beginning, the SHCS was an open, longitudinal cohort, enrolling continuously individuals from all transmission groups. In 2003 the “Swiss Mother and Child HIV Cohort Study” (MoCHiV) was integrated into the SHCS. Early on, the SHCS unified clinical, translational, basic, social and epidemiological science, as well more recently also nursing research. The considerable scientific impact of the SHCS and MoCHiV is illustrated by more than 1'000 publications in peer reviewed journals that directly emerged from these studies, respectively were made possible by significant contributions of the SHCS. One of the hallmarks of the SHCS is that this research network was able to rapidly respond to new scientific findings and challenges in the field. The SHCS is nationwide highly representative. At least 50% of all HIV-infected individuals living in Switzerland, 75% of all patients with AIDS and 75% of all patients on antiretroviral treatment participate in the SHCS. The SHCS has a strong impact on public health in Switzerland and includes: (i) Providing high quality data on HIV transmission, (ii) preventing HIV-transmission by optimal treatment and counseling, (iii) informing care givers on optimal screening and treatment interventions, (iv) providing key data on how to prevent and treat opportunistic infections, (v) monitoring co-infections and other  sexually transmitted infections (STI), (vi) providing behavioral data on sexual activities, on prevention measures, substance abuse, depression prevalence, employment status, and activities of daily living, (vii) performing cost effectiveness studies with regard to diagnostic procedures, (viii) monitoring transmission of HIV drug resistance, (ix) continuously delivering high quality data for prevention campaigns, (x) providing feedback to physicians on treatment outcome and mortality compared to other settings. 
Direct link to Lay Summary Last update: 13.11.2017

Responsible applicant and co-applicants

Employees

Project partner

Natural persons


Name Institute

Associated projects

Number Title Start Funding scheme
201369 Swiss HIV Cohort Study 01.07.2021 Cohort Studies Large
148522 Swiss HIV Cohort Study (SHCS) 01.01.2014 Cohort Studies Large
134277 Swiss HIV Cohort Study (SHCS) 01.01.2011 Cohort Studies Large
179567 The role of sexual behaviour dynamics and treatment-as-prevention in the spread of HIV, Hepatitis C and syphilis: Predicting the conditions for control and elimination 01.07.2018 Project funding (special)
108787 Swiss HIV Cohort Study 01.04.2006 Cohort Studies Large

Abstract

The Swiss HIV Cohort Study (SHCS), established in 1988, is an ongoing, longitudinal, clinic-based cohort of HIV-1 infected adults. Until to date, cumulatively, >20'000 persons have been enrolled. The strength of the cohort is the comprehensive collection of clinical, laboratory and socio-demographic data every 3 - 6 months as well as biological samples from enrolled individuals every 6-12 months, accompanied by a strict quality control program. The size and duration of the cohort allowed for the formation of a world-wide exceptional biobank which currently contains > 1.3 mio specimens from HIV infected individuals and thereby provides a unique research platform for clinical, translational, epidemiological, social and basic research worldwide. Due to its continuing success in recruiting patients, the SHCS is representative of the Swiss HIV-1 infected population. Likewise, due to its longevity, comprehensive and high quality data collection, the SHCS will continue to provide invaluable data for public health as best evidenced by the major impact on the high quality of HIV care the SHCS has had in Switzerland. An important reason for this success remains that all key players in Swiss HIV medicine are participating in the SHCS which guarantees that research results are rapidly transformed into clinical care. With its drug resistance database containing > 23000 pol genotypes and its host genetic database of > 3500 genome wide Genome typing data, 500 exomes, the SHCS is in a position to actively contribute to large international collaborations to resolve research questions that cannot be resolved by single cohorts. Key to success of the SHCS are also two further important factors, the clear dedication to a multidisciplinary approach, which promotes crossing of conventional research areas and the system of nested research projects that allows bottom up, to rapidly respond to the needs of the continuously changing HIV epidemic.
-